Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma

about

Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?

P2860

Q49375952-0471C865-A8B1-43C2-AD18-2B6223DD3C93

P2860

Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma

Item

http://www.wikidata.org/entity/Q57904195

description

im Februar 2016 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в лютому 2016

@uk

name

Lenalidomide with low- or inte ...... relapsed or refractory myeloma

@en

Lenalidomide with low- or inte ...... relapsed or refractory myeloma

@nl

type

Item

label

Lenalidomide with low- or inte ...... relapsed or refractory myeloma

@en

Lenalidomide with low- or inte ...... relapsed or refractory myeloma

@nl

prefLabel

Lenalidomide with low- or inte ...... relapsed or refractory myeloma

@en

Lenalidomide with low- or inte ...... relapsed or refractory myeloma

@nl

P1476

Lenalidomide with low- or inte ...... relapsed or refractory myeloma

@en

P2093

Despoina Kalapanida

http://www.w3.org/2001/XMLSchema#string

Dimitrios Christoulas

http://www.w3.org/2001/XMLSchema#string

Evangelos Eleutherakis-Papaiakovou

http://www.w3.org/2001/XMLSchema#string

Evangelos Terpos

http://www.w3.org/2001/XMLSchema#string

Flora Zagouri

http://www.w3.org/2001/XMLSchema#string

Magdalini Migkou

http://www.w3.org/2001/XMLSchema#string

Maria Gavriatopoulou

http://www.w3.org/2001/XMLSchema#string

Maria Roussou

http://www.w3.org/2001/XMLSchema#string

Nikolaos Kanellias

http://www.w3.org/2001/XMLSchema#string

P2860

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.

International uniform response criteria for multiple myeloma.

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Lenalidomide in multiple myeloma-a practice guideline.

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.

P304

1776-1780

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2016.1151513

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Efstathios Kastritis

P577

2016-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26916452

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone

Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma

about

P2860

P2860

Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921